Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

(B) The Edwards Sapien™ (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional aortic valve.

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery.

This is a nonsurgical means of replacing a faulty aortic heart valve without resorting to open-heart surgery. It's also Edwards' biggest moneymaker. But fourth-quarter sales will grow less than ...

for its Aortic Valve Stenosis (AVS) ECG-based artificial intelligence (AI) screening software. "Edwards Lifesciences announces positive results in one year TAVI trial" was originally created and ...

Catheter assessment of Starr-Edwards prosthetic aortic valve stenosis requires simultaneous recording of left ventricular (LV) and aortic pressures. Passage of conventional Dacron catheters across ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...